Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:28 am
Author: Getaka|Social: XLinkedIn

Pfizer Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹3,245.10Overvalued by 33.13%vs CMP ₹4,853.00

P/E (29.2) × ROE (16.4%) × BV (₹841.00) × DY (0.72%)

₹2,019.33Overvalued by 58.39%vs CMP ₹4,853.00
MoS: -140.3% (Negative)Confidence: 70/100 (High)Models: All 10: Overvalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹3,467.6920%Over (-28.5%)
Graham NumberEarnings₹1,878.9314%Over (-61.3%)
Earnings PowerEarnings₹1,148.8412%Over (-76.3%)
DCFCash Flow₹2,721.7812%Over (-43.9%)
Net Asset ValueAssets₹841.376%Over (-82.7%)
EV/EBITDAEnterprise₹2,096.978%Over (-56.8%)
Dividend DiscountDividends₹727.548%Over (-85%)
Earnings YieldEarnings₹1,865.706%Over (-61.6%)
ROCE CapitalReturns₹1,945.428%Over (-59.9%)
Revenue MultipleRevenue₹747.925%Over (-84.6%)
Consensus (10 models)₹2,019.33100%Overvalued
Key Drivers: Wide model spread (₹728–₹3,468) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 6.9%

*Investments are subject to market risks

Analyst Summary

Pfizer Ltd operates in the Pharmaceuticals segment, current market price is ₹4,853.00, market cap is 22,201 Cr.. At a glance, stock P/E is 29.2, ROE is 16.4 %, ROCE is 21.6 %, book value is 841, dividend yield is 0.72 %. The latest intrinsic value estimate is ₹2,019.33, around 58.4% below the current price, so expectations may already be running ahead of this modelled fair value. On operating trend, latest reported sales are about ₹2,281 Cr versus the prior period change of 4.0%, while latest net profit is about ₹768 Cr with a prior-period change of 39.4%. The 52-week range shown on this page is 5,993/3,701, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisPfizer Ltd. is a Public Limited Listed company incorporated on 21/11/1950 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24231MH19…

This summary is generated from the stock page data available for Pfizer Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

76
Pfizer Ltd scores 76/100 (Strong)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health87/100 · Strong
ROCE 21.6% ExcellentROE 16.4% GoodD/E 0.00 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money60/100 · Moderate
FII holding up 0.53% (6mo) Slight increasePromoter holding at 63.9% Stable
Earnings Quality60/100 · Moderate
OPM stable around 31% SteadyWorking capital: 23 days (improving) Efficient
Quarterly Momentum90/100 · Strong
Revenue (4Q): +11% YoY GrowingProfit (4Q): +39% YoY StrongOPM: 35.0% (up 8.0% YoY) Margin expansion
Industry Rank70/100 · Strong
P/E 29.2 vs industry 53.8 Cheaper than peersROCE 21.6% vs industry 16.4% Above peers3Y sales CAGR: -4% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:28 am

Market Cap 22,201 Cr.
Current Price 4,853
Intrinsic Value₹2,019.33
High / Low 5,993/3,701
Stock P/E29.2
Book Value 841
Dividend Yield0.72 %
ROCE21.6 %
ROE16.4 %
Face Value 10.0
PEG Ratio4.26

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Pfizer Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Pfizer Ltd 22,201 Cr. 4,853 5,993/3,70129.2 8410.72 %21.6 %16.4 % 10.0
Wockhardt Ltd 20,598 Cr. 1,268 1,870/1,087190 2810.00 %3.75 %1.22 % 5.00
Astrazeneca Pharma India Ltd 19,630 Cr. 7,852 10,691/6,50294.4 3200.41 %33.4 %23.6 % 2.00
Acutaas Chemicals Ltd 19,093 Cr. 2,332 2,688/93066.5 1730.06 %19.9 %16.0 % 5.00
ERIS Lifesciences Ltd 18,152 Cr. 1,310 1,910/1,09740.9 2270.56 %12.2 %12.9 % 1.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Pfizer Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 622573531575540547563589538592603642645
Expenses 418391421393387357385399392364393412417
Operating Profit 203182111183153189177189146228210230228
OPM % 33%32%21%32%28%35%32%32%27%38%35%36%35%
Other Income 2712333644754243432176742-20
Interest 4333372223322
Depreciation 26261615181415151516141414
Profit before tax 201165126201176244203215172426260255192
Tax % 25%21%26%26%26%27%26%26%26%22%26%26%26%
Net Profit 15113094149130179151158128331192189142
EPS in Rs 32.9328.3420.4432.5628.4139.1032.9434.6127.8972.3441.9141.3231.00

Last Updated: February 16, 2026, 2:43 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 16, 2026, 2:43 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 1,1121,8532,0121,9661,9692,0822,1522,2392,6112,4252,1932,2812,482
Expenses 8721,4381,5791,6161,4681,5161,5781,5261,7751,6161,5551,5401,587
Operating Profit 239414433350501566574712836809638742896
OPM % 22%22%22%18%25%27%27%32%32%33%29%33%36%
Other Income 10944972321141671838163134185344306
Interest 1212121115111315810
Depreciation 825058636671103109115106626159
Profit before tax 3402074705175486606426697738247461,0161,133
Tax % 35%66%35%35%34%35%21%26%21%24%26%24%
Net Profit 22170305337360429509498613624551768854
EPS in Rs 74.0115.2666.6773.6278.7193.79111.29108.77133.90136.38120.52167.79186.57
Dividend Payout % 486%82%22%27%25%24%297%32%26%51%29%98%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-68.33%335.71%10.49%6.82%19.17%18.65%-2.16%23.09%1.79%-11.70%39.38%
Change in YoY Net Profit Growth (%)0.00%404.04%-325.22%-3.67%12.34%-0.52%-20.81%25.25%-21.30%-13.49%51.08%

Pfizer Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Last Updated: September 5, 2025, 12:15 pm

Balance Sheet

Last Updated: January 7, 2026, 4:12 pm

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 30464646464646464646464646
Reserves 6291,9272,1182,3732,6372,9663,3502,3472,8193,1623,5504,1723,803
Borrowings 0222222633941404143
Other Liabilities 3186387228401,0049261,007810997752593653714
Total Liabilities 9772,6142,8883,2613,6903,9404,4053,2663,9014,0014,2294,9114,606
Fixed Assets 20944925902950886973894869749713724701
CWIP 313315101318088
Investments 4443370000000000
Other Assets 9091,6141,9232,3432,7393,0543,4322,3693,0303,2443,5164,1803,897
Total Assets 9772,6142,8883,2613,6903,9404,4053,2663,9014,0014,2294,9114,606

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 13211334532933298323427667356257660
Cash from Investing Activity + 10368-701-250-238351,530-469-575-3654-71
Cash from Financing Activity + -1,360-1-62-83-110-110-164-1,571-181-346-235-205
Net Cash Flow -1,125181-417-3-17231,690-1,613-88-2675383
Free Cash Flow 13093398394262125343410654292291783
CFO/OP 107%62%120%146%105%59%93%89%107%81%64%110%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow239.00412.00431.00348.00499.00564.00572.00649.00797.00768.00598.00701.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 573226202930291820233131
Inventory Days 148191167148147189198199173175200214
Days Payable 156165157178245213197130102917768
Cash Conversion Cycle 495836-10-696318791107154177
Working Capital Days 257-9-47-57-16-83-14-42423
ROCE %29%24%22%17%21%23%20%23%29%26%22%22%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%
FIIs 2.80%2.81%2.82%3.03%3.32%3.22%3.54%2.74%2.18%2.40%2.60%2.71%
DIIs 14.89%14.89%15.00%15.15%15.32%15.83%16.03%16.80%17.10%17.23%17.11%17.05%
Public 18.38%18.37%18.24%17.87%17.42%17.00%16.50%16.54%16.79%16.45%16.37%16.32%
No. of Shareholders 1,17,1941,15,9881,16,9481,12,4561,09,2141,06,09898,8241,05,0151,08,2611,03,2221,03,4801,00,933

Shareholding Pattern Chart

No. of Shareholders

Pfizer Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Nippon India Small Cap Fund 1,206,103 0.84 550.42947,9102025-12-08 07:42:1327.24%
Quant Small Cap Fund 914,527 1.52 417.35875,0272025-12-15 09:05:474.51%
ICICI Prudential Smallcap Fund 365,366 2.05 166.74360,0002026-02-22 10:27:061.49%
Nippon India Multi Cap Fund 358,673 0.34 163.68362,8482026-02-22 10:27:06-1.15%
ICICI Prudential Value Fund 356,622 0.27 162.75347,0012026-02-23 07:11:392.77%
Nippon India Pharma Fund 318,249 1.84 145.24293,2492025-12-08 04:19:428.53%
UTI Mid Cap Fund 250,000 0.99 114.09246,2762026-02-23 02:04:121.51%
DSP Healthcare Fund 200,644 3.08 91.57N/AN/AN/A
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund 180,970 1.24 82.59N/AN/AN/A
DSP Large & Mid Cap Fund 178,101 0.47 81.28N/AN/AN/A

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 136.46120.51128.50133.89108.77
Diluted EPS (Rs.) 167.79120.51136.38133.89108.77
Cash EPS (Rs.) 181.07134.12159.44159.03132.68
Book Value[Excl.RevalReserv]/Share (Rs.) 921.84785.91701.05626.10523.07
Book Value[Incl.RevalReserv]/Share (Rs.) 921.84785.91701.05626.10523.07
Dividend / Share (Rs.) 165.0035.0070.0035.0035.00
Revenue From Operations / Share (Rs.) 498.65479.38530.00570.71489.30
PBDIT / Share (Rs.) 199.45178.32198.89196.37173.38
PBIT / Share (Rs.) 186.16164.71175.82171.23149.47
PBT / Share (Rs.) 222.10163.07180.11168.94146.17
Net Profit / Share (Rs.) 167.78120.51136.38133.89108.77
PBDIT Margin (%) 39.9937.1937.5234.4035.43
PBIT Margin (%) 37.3334.3533.1730.0030.54
PBT Margin (%) 44.5334.0133.9829.6029.87
Net Profit Margin (%) 33.6425.1325.7323.4622.22
Return on Networth / Equity (%) 18.2015.3319.4521.3820.79
Return on Capital Employeed (%) 19.6120.4624.0525.7027.44
Return On Assets (%) 15.6213.0315.5915.7015.23
Asset Turnover Ratio (%) 0.490.530.610.720.58
Current Ratio (X) 6.175.073.842.812.49
Quick Ratio (X) 5.334.273.212.281.92
Inventory Turnover Ratio (X) 5.020.780.790.800.77
Dividend Payout Ratio (NP) (%) 20.8633.1947.6526.13303.38
Dividend Payout Ratio (CP) (%) 19.3329.8240.7622.00248.70
Earning Retention Ratio (%) 79.1466.8152.3573.87-203.38
Cash Earning Retention Ratio (%) 80.6770.1859.2478.00-148.70
Interest Coverage Ratio (X) 108.5052.9467.9585.6452.50
Interest Coverage Ratio (Post Tax) (X) 71.7236.2645.1359.3933.93
Enterprise Value (Cr.) 15519.5917140.8213990.3218276.3719572.81
EV / Net Operating Revenue (X) 6.807.825.777.008.74
EV / EBITDA (X) 17.0121.0115.3820.3424.67
MarketCap / Net Operating Revenue (X) 8.038.756.547.629.24
Retention Ratios (%) 79.1366.8052.3473.86-203.38
Price / BV (X) 4.345.344.946.958.64
Price / Net Operating Revenue (X) 8.038.756.547.629.24
EarningsYield 0.040.020.030.030.02

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Pfizer Ltd. is a Public Limited Listed company incorporated on 21/11/1950 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24231MH1950PLC008311 and registration number is 008311. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 2281.35 Cr. and Equity Capital is Rs. 45.75 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsThe Capital, 1802 / 1901, 18th Floor, Mumbai Maharashtra 400051Contact not found
Management
NamePosition Held
Mr. Pradip ShahChairman & Ind.Director
Ms. Meenakshi NevatiaManaging Director
Mr. P RenganExecutive Director - Operations
Mr. Amit AgarwalExecutive Director & CFO
Ms. Meena GaneshIndependent Director
Mr. Lakshmanan KrishnakumarIndependent Director
Ms. Sonia SinghIndependent Director

FAQ

What is the intrinsic value of Pfizer Ltd and is it undervalued?

As of 20 April 2026, Pfizer Ltd's intrinsic value is ₹2019.33, which is 58.39% lower than the current market price of ₹4,853.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (16.4 %), book value (₹841), dividend yield (0.72 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Pfizer Ltd?

Pfizer Ltd is trading at ₹4,853.00 as of 20 April 2026, with a FY2026-2027 high of ₹5,993 and low of ₹3,701. The stock is currently in the middle of its 52-week range. Market cap stands at ₹22,201 Cr..

How does Pfizer Ltd's P/E ratio compare to its industry?

Pfizer Ltd has a P/E ratio of 29.2, which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is Pfizer Ltd financially healthy?

Key indicators for Pfizer Ltd: ROCE of 21.6 % indicates efficient capital utilization; ROE of 16.4 % shows strong shareholder returns. Dividend yield is 0.72 %.

Is Pfizer Ltd profitable and how is the profit trend?

Pfizer Ltd reported a net profit of ₹768 Cr in Mar 2025 on revenue of ₹2,281 Cr. Compared to ₹613 Cr in Mar 2022, the net profit shows an improving trend.

Does Pfizer Ltd pay dividends?

Pfizer Ltd has a dividend yield of 0.72 % at the current price of ₹4,853.00. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Pfizer Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports